Bengaluru, Karnataka, India, October 2025 — Neelkanth Chandgothia has been appointed as Global Head – Corporate Finance at Biocon Biologics, reporting to the CFO. With more than 20 years of diverse experience in finance, strategy, and leadership, he brings a proven track record of driving high-value transformations and strengthening financial operations across multiple industries.
In his new role, Neelkanth will lead the Corporate Finance function at Biocon Biologics, overseeing financial planning, budgeting, forecasting, treasury management, tax, compliance, and governance. His leadership will be instrumental in supporting the company’s global growth ambitions while ensuring strong financial controls and operational excellence.
Before joining Biocon Biologics, Neelkanth served as Financial Controller at Jubilant FoodWorks Ltd., where he strengthened the company’s financial processes and reporting frameworks. Previously, he held progressive leadership roles at Bharti Airtel, including Vice President Finance, General Manager, and Deputy General Manager, where he contributed to organizational efficiency, policy development, and transformation initiatives.
Earlier in his career, he gained significant audit and advisory experience at EY as Senior Audit Manager and Audit Manager, and at PwC, where he worked for over a decade, building expertise in compliance, risk management, and financial governance. His journey from associate to assistant manager at PwC gave him a strong foundation in financial operations and client advisory.
A Chartered Accountant from The Institute of Chartered Accountants of India (ICAI), Neelkanth combines deep technical expertise with a strategic approach to finance. His appointment reflects Biocon Biologics’ commitment to strengthening its finance leadership and advancing its mission to deliver affordable and accessible healthcare solutions worldwide.
About Biocon Biologics
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization leveraging cutting-edge science, advanced research, and innovative technology platforms to improve healthcare outcomes while lowering treatment costs.
With a strong pipeline of biosimilars across therapeutic areas such as diabetes, oncology, immunology, and other non-communicable diseases, Biocon Biologics has successfully taken six molecules from lab to market across major developed regions including the United States, EU, Australia, Canada, and Japan. Supported by a team of nearly 4,800 professionals, the company is dedicated to transforming healthcare and enabling affordable access for millions of patients worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
